These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2313 related items for PubMed ID: 3556777

  • 21. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ, Robertson PW, Whybin LR.
    Med J Aust; 1994 Apr 18; 160(8):478-82. PubMed ID: 8170422
    [Abstract] [Full Text] [Related]

  • 22. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA, Barakat SS, Abd El Fattah MM, Said ZN, El Metwally HA.
    East Mediterr Health J; 2009 Apr 18; 15(1):85-93. PubMed ID: 19469430
    [Abstract] [Full Text] [Related]

  • 23. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W, Bucholc B, Wysokińska T, Górska P, Gniadek G.
    Przegl Epidemiol; 2003 Apr 18; 57(2):281-8. PubMed ID: 12910596
    [Abstract] [Full Text] [Related]

  • 24. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM.
    Saudi Med J; 2006 Jan 18; 27(1):63-9. PubMed ID: 16432596
    [Abstract] [Full Text] [Related]

  • 25. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A, Eggenberger K, Steiner CA, Matter L, Germann D.
    Schweiz Med Wochenschr; 1997 Jun 28; 127(26):1124-33. PubMed ID: 9312835
    [Abstract] [Full Text] [Related]

  • 26. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 28; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 27. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP.
    Cent Eur J Public Health; 2000 Aug 28; 8(3):160-3. PubMed ID: 10965439
    [Abstract] [Full Text] [Related]

  • 28. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec 28; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 29. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 30. ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps.
    Rose VL.
    Am Fam Physician; 1998 Nov 01; 58(7):1682, 1685-6. PubMed ID: 9824963
    [No Abstract] [Full Text] [Related]

  • 31. Measles, mumps, and rubella vaccines.
    Wharton M, Cochi SL, Williams WW.
    Infect Dis Clin North Am; 1990 Mar 01; 4(1):47-73. PubMed ID: 2407778
    [Abstract] [Full Text] [Related]

  • 32. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM, Moffat MA.
    Health Bull (Edinb); 1992 Jan 01; 50(1):47-53. PubMed ID: 1612895
    [Abstract] [Full Text] [Related]

  • 33. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P.
    Ann Ig; 1998 Jan 01; 10(1):19-24. PubMed ID: 9616974
    [No Abstract] [Full Text] [Related]

  • 34. [Epidemiologic study of measles, rubella and mumps with regard to the possibility of their control by immunization].
    Rodríguez Borrego MJ, García León J, Bolumar F, Nájera E.
    Rev Sanid Hig Publica (Madr); 1985 Jan 01; 59(1-2):117-25. PubMed ID: 4059834
    [No Abstract] [Full Text] [Related]

  • 35. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, Yamamura AM, Martins RM, Leal Mde L, Collaborative Group for the Study of Yellow Fever Vaccines.
    Vaccine; 2011 Aug 26; 29(37):6327-34. PubMed ID: 21640779
    [Abstract] [Full Text] [Related]

  • 36. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination].
    Rønne T, Trier H.
    Ugeskr Laeger; 1992 Jul 13; 154(29):2014-8. PubMed ID: 1509567
    [Abstract] [Full Text] [Related]

  • 37. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
    Mrozek-Budzyn D, Kiełtyka A, Majewska R.
    Pediatr Infect Dis J; 2010 May 13; 29(5):397-400. PubMed ID: 19952979
    [Abstract] [Full Text] [Related]

  • 38. Measles and mumps immunization: benefit versus risk factors.
    Krugman S.
    Dev Biol Stand; 1979 May 13; 43():253-7. PubMed ID: 520672
    [Abstract] [Full Text] [Related]

  • 39. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 40. [35-year measles, mumps, rubella vaccination assessment in France].
    Reinert P, Soubeyrand B, Gauchoux R.
    Arch Pediatr; 2003 Nov 14; 10(11):948-54. PubMed ID: 14613687
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 116.